**ESOPHAGOASTRIC DISEASE ORIENTED GROUP**

CHELSEA HOTEL, TORONTO, ON  
ROOM: ROSSETTI  
SATURDAY APRIL 28, 2018, 1:30 PM – 2:30 PM  

CO-CHAIRS: DR. T. ALCINDOR, DR. G. DARLING, DR. A. MAHMUD  
SENIOR INVESTIGATOR: DR. CHRIS O’CALLAGHAN

---

**CME Credits:**  
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

**Learning Objectives:**

- To interpret and address, through clinical and translational research, the disease burden associated with esophagogastric malignancies in Canada.
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to esophagogastric malignancies.
- To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to esophagogastric malignancies.
- To interpret and apply new clinical trial methodologies in the field of clinical research in esophagogastric malignancies.

---

**1:30 pm**  Setting Strategic Plan

Active/Recently Closed Trials for Update  

**1:55 pm**  GA.1 (TOP GEAR): A Randomized Phase III Trial of Preoperative Chemoradiotherapy versus Preoperative Chemotherapy for Resectable Gastric Cancer  

Dr. R. Wong

**2:05 pm**  GA.3 (INTEGRATE II): A Randomized Phase 3 Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Oesophago-Gastric Cancer (AOGC)  

Dr. T. Alcindor

**2:10 pm**  New Concepts in Development  

EA2174: A Phase II Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma  

Dr. T. Alcindor

**2:20 pm**  PREHAB Trial proposal for Pre-treatment assessment and Program to Improve Patient’s Functional Status Prior to and During Treatment  

Dr. R. Wong

**2:30 pm**  Meeting Adjourned